Income Taxes (Tables)
|
12 Months Ended |
Dec. 31, 2024 |
| Income Tax Disclosure [Abstract] |
|
| Schedule of Income Tax Expense (Benefit) |
The
Company recorded the below income tax expense (benefit) attributable to income from continuing operations for the year ending December
31, 2024 and December 31, 2023 as follows:
Schedule of Income Tax Expense (Benefit)
| |
|
|
|
|
|
|
|
|
| |
|
December
31, |
|
| |
|
2024 |
|
|
2023 |
|
| |
|
(In
thousands, except percentages) |
|
| Current |
|
|
|
|
|
|
|
|
| Federal |
|
$ |
(7 |
) |
|
$ |
-
|
|
| State |
|
|
21 |
|
|
|
- |
|
| Foreign |
|
|
(34 |
) |
|
|
- |
|
| Current,
Total |
|
|
(20 |
) |
|
|
- |
|
| Deferred |
|
|
|
|
|
|
|
|
| Federal |
|
|
- |
|
|
|
- |
|
| State |
|
|
- |
|
|
|
- |
|
| Foreign |
|
|
- |
|
|
|
- |
|
| Deferred,
Total |
|
|
- |
|
|
|
- |
|
| Total
income tax expense |
|
$ |
(20 |
) |
|
$ |
- |
|
|
| Schedule of Effective Income Tax Rate Reconciliation |
The
reconciliation of the provision computed at the federal statutory rate to the Company’s provision (benefit) for income taxes as
follows:
Schedule of Effective Income Tax Rate Reconciliation
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
December
31, |
|
| |
|
2024 |
|
|
2023 |
|
| |
|
(In
thousands, except percentages) |
|
| Tax
at federal statutory rate |
|
$ |
(15,432 |
) |
|
|
(21.0 |
)% |
|
$ |
(28,354 |
) |
|
|
(21.0 |
)% |
| State,
net of federal benefit |
|
|
12,779 |
|
|
|
17.4 |
% |
|
|
(6,507 |
) |
|
|
(4.8 |
)% |
| Stock
based compensation |
|
|
3,327 |
|
|
|
3.8 |
% |
|
|
967 |
|
|
|
0.7 |
% |
| Fair value adjustments |
|
|
(7,593 |
) |
|
|
(9.6 |
)% |
|
|
(3,555 |
) |
|
|
(2.4 |
)% |
| Research
and development credits |
|
|
— |
|
|
|
— |
% |
|
|
(1,121 |
) |
|
|
(0.8 |
)% |
| Section
382 Limitation |
|
|
14,583 |
|
|
|
19.8 |
% |
|
|
|
|
|
|
|
|
| Other |
|
|
(745 |
) |
|
|
(1.0 |
)% |
|
|
675 |
|
|
|
0.2 |
% |
| Change
in valuation allowance |
|
|
(6,939 |
) |
|
|
(9.4 |
)% |
|
|
37,895 |
|
|
|
28.1 |
% |
| Total
provision for income taxes |
|
$ |
(20 |
) |
|
|
— |
% |
|
$ |
— |
|
|
|
— |
% |
|
| Schedule of Components of Deferred Tax Assets and Liabilities |
Schedule
of Components of Deferred Tax Assets and Liabilities
| |
|
|
|
|
|
|
|
|
| |
|
December
31, |
|
| |
|
2024 |
|
|
2023 |
|
| |
|
(In
thousands) |
|
| Deferred
tax assets |
|
|
|
|
|
|
|
|
| Net
operating loss carryforwards |
|
$ |
81,649 |
|
|
$ |
91,668 |
|
| Research
and development tax credits |
|
|
5,086 |
|
|
|
12,087 |
|
| Stock
based compensation |
|
|
5,866 |
|
|
|
6,162 |
|
| Lease
liability |
|
|
2,632 |
|
|
|
3,098 |
|
| Section
174 research and development capitalization |
|
|
10,691 |
|
|
|
11,641 |
|
| Interest
expense |
|
|
7,157 |
|
|
|
3,063 |
|
| Other
timing differences |
|
|
8,754 |
|
|
|
1,408 |
|
| Total
deferred tax assets |
|
$ |
121,835 |
|
|
$ |
129,127 |
|
| Valuation
allowance |
|
$ |
(118,783 |
) |
|
$ |
(125,722 |
) |
| Net
deferred tax assets |
|
$ |
3,052 |
|
|
$ |
3,405 |
|
| |
|
|
|
|
|
|
|
|
| Deferred
tax liabilities |
|
|
|
|
|
|
|
|
| Fixed
assets and intangibles |
|
$ |
(299 |
) |
|
$ |
(364 |
) |
| Right
of use assets |
|
$ |
(2,753 |
) |
|
$ |
(3,041 |
) |
| Total
deferred tax liabilities |
|
$ |
(3,052 |
) |
|
$ |
(3,405 |
) |
| Net
deferred tax assets |
|
$ |
— |
|
|
$ |
— |
|
|
| Schedule of Unrecognized Tax Benefits Roll Forward |
A
reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:
Schedule of Unrecognized Tax Benefits Roll Forward
| |
|
|
|
|
|
|
|
|
| |
|
December
31, |
|
| |
|
2024 |
|
|
2023 |
|
| |
|
(In
thousands) |
|
| Balance
at beginning of year |
|
$ |
6,060 |
|
|
$ |
4,750 |
|
| Additions
based on tax positions related to the current year |
|
|
(3,301 |
) |
|
|
1,310 |
|
| Balance
at end of year |
|
$ |
2,759 |
|
|
$ |
6,060 |
|
|